Drugs / SHR-2106
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05948059 | Jul 2023 → May 2024 | — | Guangdong Hengrui Pharmaceutical Co., Ltd | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SHR-2106 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05948059 ↗ |
| Route | Intravenous | “single intravenous or subcutaneous administration of SHR-2106” NCT05948059 ↗ |
| Route | Subcutaneous | “single intravenous or subcutaneous administration of SHR-2106” NCT05948059 ↗ |